 the nonsigniﬁcant increase in the primary composite outcome as well as by an increase in
clinically relevant nonmajor bleeding in the rivaroxaban
group. These recommendations are similar to those,
published recently on management of SVT in the CHEST
guidelines.253
Low-quality evidence in one study found that prophylactic LMWH reduced extension of SVT (statistically signiﬁcant), but did not reduce incidence of VTE, while
therapeutic